Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Announces Presentation of Two Abstracts at AACR
Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session
View HTML
Toggle Summary NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results
Management to Host Conference Call and Webcast Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on February 28, 2017
AMES, Iowa , Feb. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday, February 28, 2017 .  The company has scheduled a conference call for 8:30 AM ET the same day to discuss
View HTML
Toggle Summary NewLink Genetics to Participate in 2017 SunTrust Orphan Drug Day on February 14th
AMES, Iowa , Feb. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the 2017 SunTrust Robinson Humphrey Orphan Drug Day on
View HTML
Toggle Summary NewLink Genetics to Participate in Three Investor Conferences in November
AMES, Iowa , Nov. 09, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the Global Mizuho Investor Conference on November 14 , the
View HTML
Toggle Summary NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2016 Financial Results
Management to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics Shares Its Immuno-Oncology Strategy 2016 Analyst and Investor Day
Two Distinct IDO Pathway Inhibitors in Clinical Development Indoximod, Exclusive to NewLink Genetics GDC-0919 in Partnership with Genentech , a Member of the Roche Group AMES, Iowa & NEW YORK , Oct. 25, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company
View HTML
Toggle Summary NewLink Genetics to Host Its Third Quarter 2016 Financial Results Conference Call on November 1, 2016
AMES, Iowa , Oct. 24, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its third quarter 2016 financial results on Tuesday, November 1, 2016 . The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and
View HTML
Toggle Summary NewLink Genetics to Webcast 2016 Analyst and Investor Day on October 25, 2016
AMES, Iowa , Oct. 20, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will webcast its Analyst and Investor Day being held on Tuesday, October 25 at the Convene Meeting Center in New York City . The Analyst and Investor Day will be webcast live and a link
View HTML
Toggle Summary NewLink Genetics Awarded $25 Million Contract from BARDA for Investigational Ebola Zaire Vaccine (V920)
AMES, Iowa , Oct. 04, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has issued a $24.8 million contract to a subsidiary
View HTML